MIMIVAX, LLC

BUFFALO, NY · Biotech · Private

SurVaxM, a peptide mimic immunotherapeutic vaccine targeting survivin for cancer treatment

Claim this profile

Follows are private to you and power your alerts

Updated · mimivax.com

Sector
Biotech
Headquarters
BUFFALO, NY
Latest Form D
$5.8M, Jul 2024
Total capital
$6.2M
Federal grants
$464K
1 award · 2022
Rank in peer group#291 of 502
Private capital raised
$5.8M
1 Form D · last Jul 2024
27 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202220232024FEDERAL ↑EQUITY ↓Cumulative $6.2M$464K1st Form D$5.8M
202220232024FEDERAL ↑EQUITY ↓Cumulative $6.2M$464K1st Form D$5.8M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$5.8M
  • Federal grantHealth and Human S · Phase I · MV2C2 antibody as a new therapeutic for Myasthenia Gravis$464K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

22months

from MIMIVAX, LLC’s first federal award to its first private round.

First federal award · Aug 2022
Health and Human S · $464K
First Form D · Jul 2024
$5.8M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Michael CiesielskiResearcherDirectorLinked by $464K in grants as PI
  • Jeremy Jacobs Jr.DirectorNamed in SEC Form D filings
  • Jeremy Jacobs, Jr.Executive OfficerNamed in SEC Form D filings
  • Michael SextonDirectorNamed in SEC Form D filings
  • Robert FenstermakerDirectorNamed in SEC Form D filings
  • Scott FriedmanDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Mitokinin, Inc.Similar federal contract value in Biotech · null in contracts
  • Suono Bio Inc.Similar federal contract value in Biotech · null in contracts
  • EnBiotix, Inc.Similar federal contract value in Biotech · null in contracts
  • T3D Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Novosteo Inc.Similar federal contract value in Biotech · null in contracts
  • Everest Biolabs, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .